Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Chemotherapy drug may increase kidney damage risk

  • Comment

The chemotherapy drug bevacizumab (Avastin) may put cancer patients at increased risk of severe kidney damage, according to US research.

The study, which involved more than 12,000 patients, found the drug could put patients at increased risk of severe loss of protein from the kidney into the urine, potentially leading to significant kidney damage.

The research, carried out by the Stony Brook University Medical Centre in Stony Brook, New York, is reported in the Journal of the American Society Nephrology.



  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.